Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Amgen's Denosumab Trumps Zometa with Top-Line Results for Cancer Bone Complications

This article was originally published in The Pink Sheet Daily

Executive Summary

Amgen has great expectations for denosumab, but the drug still has a long road ahead and an upcoming FDA Advisory Committee review before it hits the market.

You may also be interested in...



With $30M In Hand, Zosano Hopes Its Osteoporosis Patch Will Compete With Forteo

Despite a long list of potential therapeutic uses for its transdermal patch technology, privately held biotech seeks direct competition in osteoporosis anabolic therapy space.

With $30M In Hand, Zosano Hopes Its Osteoporosis Patch Will Compete With Forteo

Despite a long list of potential therapeutic uses for its transdermal patch technology, privately held biotech seeks direct competition in osteoporosis anabolic therapy space.

Will Safety Issues Derail Denosumab? FDA Sets Advisory Cmte. Slot

Amgen’s much-ballyhooed monoclonal antibody, now called Prolia, faces safety questions at the Aug. 13 Advisory Committee for Reproductive Health Drugs meeting.

Topics

UsernamePublicRestriction

Register

ID1122310

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel